Article Information
History
- June 13, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Seth Toback1,
- Eva Galiza2,
- Catherine Cosgrove2,
- James Galloway3,
- Anna L. Goodman4,
- Pauline A. Swift5,
- Sankarasubramanian Rajaram6,
- Alison Graves-Jones7,
- Jonathan Edelman8,
- Fiona Burns9,
- Angela M. Minassian10,
- Iksung Cho1,
- Lakshmi Kumar1,
- Joyce S. Plested1,
- E. Joy Rivers1,
- Andreana Robertson1,
- Filip Dubovsky1,
- Greg Glenn1,†,
- Paul T. Heath2 and
- on behalf of the 2019nCoV-302 Study Group*
- 1Novavax, Inc., Gaithersburg, MD, USA
- 2Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
- 3Centre for Rheumatic Disease, King’s College London, London, UK
- 4Department of Infectious Diseases, Guy’s and St Thomas’ NHS Foundation Trust, and MRC Clinical Trials Unit at University College London, London, UK
- 5Department of Nephrology, Epsom and St. Helier University Hospitals NHS Trust, London, UK
- 6Seqirus UK Limited, Maidenhead, UK
- 7Seqirus Australia Pty. Ltd., Melbourne, Australia
- 8Seqirus USA Inc., Summit, NJ, USA
- 9Institute for Global Health, University College London, and Royal Free London NHS Foundation Trust
- 10Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
- ↵†Correspondence to:
Prof. Paul T. Heath, FRCPCH, Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK; Email: pheath{at}sgul.ac.uk
Posted June 13, 2021.
Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
